Study #2014-1029
Pilot Study of The Feasibility And Safety Of A Personalized Peptide Vaccine In Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma
MD Anderson Study Status
Enrolling
Treatment Agent
Imiquimod, Synthetic Tumor-Associated Peptide Vaccine Therapy, Pembrolizumab, Sotigalimab
Description
This phase I trial studies the side effects and best way to give personalized peptide vaccine in patients with pancreatic or colorectal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Personalized peptide vaccine is a vaccine developed from patient's own tumor cells and blood in order to use as a biological therapy. Biological therapies, such as personalized peptide vaccine may attack tumor cells and stop them from growing or kill them.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
Study phase:
Phase I
Physician name:
Michael Overman
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-877-211-1427
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.